Curious how base editing works? Check out our animation and learn how the #BeamTeam is tackling diseases one letter at a time! #DaretoBeam
Beam Therapeutics
生物技术研究
Cambridge，Massachusetts 68,826 位关注者
Our vision is to provide life-long cures for patients suffering from serious diseases.
关于我们
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: ? A community of fearless innovators ? Rigorous and honest in our research ? Listening with open minds ? Committed to each other
- 网站
-
https://beamtx.com
Beam Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2017
- 领域
- gene therapy、base editing、gene editing、precision medicines、CRISPR、CRISPR Cas9、genetic diseases、rare diseases、hematology、lipid nanoparticles、LNP、vector production、AAV、In vivo、ex vivo、Liver、mRNA Production、mRNA、DNA、RNA、Cas9、drug development、drug delivery、immunology、formulation development、virology、viral delivery、nanoparticles formulation、structural biology、cell biology、protein sciences和cell therapy
地点
-
主要
获取路线
238 Main St
US，Massachusetts，Cambridge，02142
Beam Therapeutics员工
动态
-
This #BlackHistoryMonth, we celebrated in Cambridge and North Carolina with a Black History Month happy hour and trivia. The #BeamTeam loves a friendly competition! #DaretoBeam
-
-
For #RareDiseaseDay, we are sharing Heather's story of living with Alpha-1 https://lnkd.in/ebfnYEJE
Living with Alpha-1: Heather's Story
https://www.youtube.com/
-
Today, Beam reported fourth quarter and full year 2024 financial results and reiterated anticipated milestones across the company’s hematology and genetic disease franchises. Read the full press release here: https://lnkd.in/dwaW2F2U #DaretoBeam #BeamTeam
-
-
Today, we announced that management will participate in fireside chats at several upcoming March investor conferences. More on these conferences here: https://lnkd.in/e2JSGtEh #BeamTeam #DaretoBeam
-
-
The #BeamTeam's,?Priya S. Chockalingam, VP, Head of Clinical BioAnalytics & Translational Sciences, will join the rare disease community, including industry leaders and advocates, at The Boston Globe Media's Rare Disease Summit on Tuesday, February 25th. Learn more about the session: Pioneering Breakthroughs in Gene Therapy and how you can join in person or virtually here:?https://lnkd.in/ezPDp_95?#DaretoBeam
-
-
This morning, Beam announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at ASTCT and CIBMTR taking place February 12 – 15, 2025, in Honolulu, Hawaii. Learn more here: https://lnkd.in/d5nwVY2m #BeamTeam #DaretoBeam
-
-
The #BeamTeam is growing in North Carolina! We're #hiring across many functions at our manufacturing facility in Durham. Check out our open roles here and #DaretoBeamNC #DaretoBeam https://lnkd.in/erRWS_KU
-
-
Today, Beam announced progress across our hematology and genetic disease franchises and provided updates on anticipated upcoming milestones. Read the full update here: https://lnkd.in/eY7Vhz53 #BeamTeam #DaretoBeam #JPM25 Beam will present and discuss pipeline and business updates during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2025, at 1:30 p.m. PT. A live webcast will be available in the investor section of the company’s website.
-
-
Congratulations to the Institute of Molecular and Clinical Ophthalmology Basel (IOB) on this exciting accomplishment! We're proud to be part of this work and the potential for base editing to transform the lives of patients with Stargardt disease. Read the IOB’s press release here:?https://lnkd.in/ebhf5xrt ? Read the paper here:?https://lnkd.in/ejNkvAaM
Head of Clinical Translation at IOB, Basel, Switzerland & Assistant Professor at University of Basel
Thrilled to share that our study on high-efficiency base editing in the retina is now published in Nature Medicine! It’s been a nearly 7-year journey with 49 team members, and we’re excited to offer a potential new avenue for treating Stargardt disease, an inherited neurodegenerative disorder of the retina. Huge thanks to everyone who contributed to this milestone! Read the paper here: https://lnkd.in/ejNkvAaM Watch the video: https://lnkd.in/d326UABB Press release here: https://lnkd.in/ebhf5xrt Institute of Molecular and Clinical Ophthalmology Basel (IOB) Beam Therapeutics University of Basel Semmelweis University Inserm UMR U1246 SPHERE - University of Nantes - University of Tours #StargardtDisease #BaseEditing #GeneTherapy #NatureMedicine #Ophthalmology #TeamScience #GeneEditing #VisionResearch #IOBBasel #BeamTherapeutics